Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125582224 | 12558222 | 4 | F | 20160711 | 20160902 | 20160714 | 20160907 | EXP | JP-ABBVIE-16P-087-1673719-00 | ABBVIE | 80.36 | YR | F | Y | 41.00000 | KG | 20160907 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125582224 | 12558222 | 1 | PS | VIEKIRAX | OMBITASVIRPARITAPREVIRRITONAVIR | 1 | Oral | Y | UNKNOWN | 207931 | TABLET | BID | |||||||
| 125582224 | 12558222 | 2 | SS | VIEKIRAX | OMBITASVIRPARITAPREVIRRITONAVIR | 1 | Oral | Y | UNKNOWN | 207931 | TABLET | BID | |||||||
| 125582224 | 12558222 | 3 | SS | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Oral | Y | 0 | TABLET | QD | ||||||||
| 125582224 | 12558222 | 4 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 0 | TABLET | ||||||||||
| 125582224 | 12558222 | 5 | C | LEVOTHYROXINE SODIUM. | LEVOTHYROXINE SODIUM | 1 | Oral | 0 | TABLET | QD | |||||||||
| 125582224 | 12558222 | 6 | C | DOXAZOSIN MESILATE | DOXAZOSIN MESYLATE | 1 | Parenteral | 0 | |||||||||||
| 125582224 | 12558222 | 7 | C | THEOPHYLLINE | THEOPHYLLINE ANHYDROUS | 1 | Oral | 0 | TABLET | BID | |||||||||
| 125582224 | 12558222 | 8 | C | SODIUM FERRIC CITRATE | FERRIC SODIUM CITRATE | 1 | Oral | 0 | TABLET | QD | |||||||||
| 125582224 | 12558222 | 9 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 0 | ORODISPERSIBLE TABLET | QD | |||||||||
| 125582224 | 12558222 | 10 | C | EPINASTINE HYDROCHLORIDE. | EPINASTINE HYDROCHLORIDE | 1 | Oral | 0 | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125582224 | 12558222 | 1 | Chronic hepatitis C |
| 125582224 | 12558222 | 3 | Nephrotic syndrome |
| 125582224 | 12558222 | 4 | Nephrotic syndrome |
| 125582224 | 12558222 | 5 | Hypothyroidism |
| 125582224 | 12558222 | 6 | Hypertension |
| 125582224 | 12558222 | 7 | Asthma |
| 125582224 | 12558222 | 8 | Anaemia |
| 125582224 | 12558222 | 9 | Gastrooesophageal reflux disease |
| 125582224 | 12558222 | 10 | Dermatitis allergic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125582224 | 12558222 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125582224 | 12558222 | Anaemia | |
| 125582224 | 12558222 | Hyperkalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125582224 | 12558222 | 1 | 20160628 | 201608 | 0 | |
| 125582224 | 12558222 | 2 | 20160721 | 0 | ||
| 125582224 | 12558222 | 3 | 20160711 | 0 | ||
| 125582224 | 12558222 | 6 | 20160225 | 0 |